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ABSTRACT
Neuroblastoma (NB) is the most common cancer in infants and it accounts for 
six percent of all pediatric malignancies. There are several hypotheses proposed 
on the origins of NB. While there is little genetic evidence to support this, the 
prevailing model is that NB originates from neural crest stem cells (NCSCs). Utilizing 
in vivo mouse models, we demonstrate that targeting MYCN oncogene to NCSCs 
causes perinatal lethality. During sympathoadrenal (SA) lineage development, SOX 
transcriptional factors drive the transition from NCSCs to lineage-specific progenitors, 
characterized by the sequential activation of Sox9/Sox10/Sox4/Sox11 genes. We 
find the NCSCs factor SOX10 is not expressed in neuroblasts, but rather restricted to 
the Schwannian stroma and is associated with a good prognosis. On the other hand, 
SOX9 expression in NB cells was associated with several key biological processes 
including migration, invasion and differentiation. Moreover, manipulating SOX9 gene 
predominantly affects lineage-restricted SA progenitors. Our findings highlight a 
unique molecular SOX signature associated with NB that is highly reminiscent of SA 
progenitor transcriptional program during embryonic development, providing novel 
insights into NB pathobiology. In summary, we provide multiple lines of evidence 
suggesting that multipotent NCSCs do not contribute to NB initiation and maintenance.
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INTRODUCTION
Neuroblastoma (NB) is a pediatric malignancy 
affecting infants and young children with median age 
at diagnosis is 17 months [1]. Multimodality treatment 
of high-risk NB can be effective, but up to fifty percent 
of children experience recurrent disease [2–4]. Despite 
various sequencing efforts to systemize and decipher 
its complexity, the biology of NB has remained largely 
elusive. The remarkable clinical and biological diversity 
of NB can vary from patient to patient and one of the 
hallmarks of NB is its unique capacity to undergo 
spontaneous regression [5]. Such composite nature of NB 
cannot be explained genetically since high-throughput 
sequencing uncovered low mutational burden in primary 
NB [6].
Several recent studies presented convincing 
evidence that in vitro NCSCs can act as a cellular 
population capable of NB initiation, when transduced with 
MYCN, ALKF1174L and ALKR1275Q oncogenes and injected 
into immunocompromised mice [7–9]. These findings and 
other notable parallels shared by NCSCs and NB cells, 
including remarkable capacity to metastasize, have led 
to a number of recent reviews proposing NCSCs as the 
cell-of-origin and CSCs in NB [10–13]. However, despite 
a growing number of reports, no definitive evidence has 
been presented to whether NCSCs can initiate NB in 
vivo in mouse models and therefore, serve as a candidate 
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cellular population as the cell-of-origin of NB. Moreover, 
no functional evidence has been obtained for the presence 
of NCSCs in human patient’s biopsies.
Here, by combining in vivo mouse genetic approach 
and the functional analysis of human NB cell lines, we 
present multiple lines of evidence that multipotent NCSCs 
do not contribute to NB initiation and maintenance. 
Comprehensive analysis of the signature NCSCs 
stemness genes, SOX10 and SOX9, in combination 
with the induction of the neural crest (NC) program by 
overexpression of SOX9, uncovered the lack of NCSCs 
within human biopsies. Notably, the genetic profile of 
NB cells shared a striking resemblance to the embryonic 
lineage-restricted progenitors expressing SOX4/SOX11 
genes. Taken together, our study provides novel insights 
into our understanding of NB biology, and lays the 
foundation for better targeted therapeutic strategies.
RESULTS
Targeting the MYCN oncogene to the neural 
crest stem cells in vivo results in perinatal 
lethality
Previous reports suggested that oncogenic 
transformation of NCSCs can initiate NB formation 
in vitro [7–9, 14]. These observations prompted us to 
investigate whether multipotent NCSCs can also serve 
as NB cell of origin in vivo. Since MYCN amplification 
is the most common genetic aberration in sporadic NB 
and occurs in approximately 25 percent of tumors [2], we 
used LSL-MYCN mice, a genetically engineered mouse 
model in which MYCN oncogene is activated upon Cre-
mediated recombination [14]. To induce the expression 
of MYCN in NCSCs, we took advantage of Sox10-Cre 
line, which allows Cre-mediated recombination from E9 
onwards (Figure 1A) [15]. The absence of mice carrying 
both transgenes at postnatal day 21 (several independent 
litters were analyzed, total n = 79 mice; Supplementary 
Figure 1A) suggested the presence of embryonic or 
perinatal lethality. As shown in Supplementary Figure 1A, 
PCR analysis revealed the presence of wild-type (WT) 
genotype in 12/79 mice, Cre genotype was detected in 
28/79 mice, LSL-MYCN genotype was present in 39/79 
mice and none of the genotyped animals carried both 
transgenes (0/79). In order to investigate whether LSL-
MYCN; Sox10-Cre mice were born alive, we genotyped 
entire litters at postnatal day 0. To increase the chance 
of pups carrying both transgenes, we crossed mice 
homozygous for LSL-MYCN allele with Sox10-Cre mice 
as shown in Supplementary Figure 1B. Based on our 
breeding scheme, we expected that 100% of resulting 
offspring should be hemizygous for LSL-MYCN allele, 
and 50% should inherit Cre transgene resulting in 
approximately 50% of pups carrying both transgenes. We 
have analyzed 16 pups at postnatal day 0 and observed the 
expected genetic distribution, 16/16 pups inherited LSL-
MYCN allele, 6/16 pups in addition to the LSL-MYCN 
allele also carried Cre transgene (Supplementary Figure 
1B). These data reveal that pups carrying LSL-MYCN; 
Sox10-Cre genotype are born at Mendelian ratio. However, 
all double transgenic LSL-MYCN; Sox10-Cre pups (n = 6) 
did not move after birth suggesting that despite developing 
to full term, these pups were likely stillborn. The possible 
mechanisms underlying this lethality might include the 
presence of a respiratory failure in these pups due to 
severe defects in sympathetic nervous system as well as 
abnormalities in other tissues and organs.
To circumvent perinatal lethality, we time-mated 
LSL-MYCN and Sox10-Cre mice and isolated embryos 
at embryonic day 18.5 (E18.5). Gross anatomical 
examination of LSL-MYCN; Sox10-Cre embryos did 
not reveal any significant abnormalities (Supplementary 
Figure 1C). To assess whether NB formed during prenatal 
development, we analyzed sympathoadrenal (SA) 
progenitors. Immunofluorescence revealed that at E18.5, 
SA progenitors in the adrenal medulla (AM) did not exhibit 
an increased proliferation as judged by anti-Th (tyrosinase 
hydroxylase) and proliferation marker Ki67 (Figure 1B 
and Supplementary Figure 1D). Of note, SA progenitors 
in the suprarenal ganglia (SrG) proliferated at a similar 
rate in both control and LSL-MYCN; Sox10-Cre embryos 
(Figure 1B). While NB tumors can develop anywhere 
in the sympathetic nervous system, the most prevalent 
anatomical location is AM (40% of localized NB and up 
to 60% of widespread disease). Nevertheless, we cannot 
rule out the possibility that NB might have originated in 
other sympathetic ganglia (SG) of LSL-MYCN; Sox10-Cre 
embryos. However, taking into account the absence of an 
increased proliferation and morphological abnormalities 
within AG and SrG, it seems to be an unlikely scenario.
Interestingly, another NB oncogene, ALKF1174L, when 
targeted to NCSCs using Sox10-Cre, also leads to lethality 
albeit at the earlier embryonic time-point [16].
Similarly to Schwann cell precursors (SCPs), 
Desert Hedgehog (Dhh)-expressing cells can give rise 
to a subpopulation of chromaffin cells in the AM, and 
therefore, can potentially be the cell-of-origin of NB 
in vivo (unpublished data) [22, 23]. To address this 
possibility, we crossed LSL-MYCN mice with Dhh-Cre 
[24] transgenic line, which drives Cre expression from E12 
onwards (Figure 1C). LSL-MYCN; Dhh-Cre mice were 
born at expected Mendelian ratio, viable and appeared 
morphologically normal. To identify the presence of 
MYCN overexpression, we used the luciferase reporter and 
performed an in vivo imaging system (IVIS) to monitor 
the MYCN-positive cells in the sympathetic chain and 
in the AM. Despite the successful induction of MYCN 
oncogene in Dhh-expressing cells we did not observe NB 
formation (mice were aged up to 8 months, Figure 1D). It 
is important to note, however, that our data cannot exclude 
that a population of SCPs molecularly distinct from Dhh-
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expressing cells still could be a candidate NB cell-of-
origin population.
In order to exclude a potential toxicity of the LSL-
MYCN transgene, we crossed LSL-MYCN mice with SA 
progenitor-specific Dbh-iCre mice and observed NB 
development as previously reported (Supplementary 
Figure 1E, 1F) [14].
Taken together, our in vivo data demonstrate that 
only SA progenitors are capable of tumor initiation in the 
context of MYCN overexpression in the transgenic mice.
Human neuroblastoma samples contain 
SOX10-expressing cells but its expression is 
predominantly found in Schwann cells
A leading hypothesis posits that NB occurs as 
a result of the deregulation of NC development via 
hijacking pathways controlling NC stemness [11, 12, 
25]. Stem cell/ progenitor identity is determined by 
lineage-specific transcription factors. To test whether 
NB cells express NCSCs lineage genes, we analyzed 
the expression of a master regulator of NCSCs identity, 
transcription factor SOX10 [26–28]. Our data reveal 
that SOX10 was expressed in human NB samples and 
was associated with a good prognosis (Figure 1E, 1F, 
n = 498, P < 0.001 and Supplementary Figure 2A–
2C). This result is somewhat counterintuitive, because 
the presence of NCSCs-like cells would rather be 
associated with more aggressive tumor behavior. 
Indeed, in melanoma, another NC-derived malignancy, 
SOX10 expression predisposes to tumor development 
and is associated with a bad prognosis [29]. In order to 
investigate SOX10 expression on a cellular level, we have 
performed immunohistochemical analysis of NB tissue 
derived from two independent genetically engineered 
mouse models (TH-MYCN [30] and LSL-MYCN; Dbh-
iCre [14]). Strikingly, SOX10 expression was restricted to 
Schwann cells and absent from tumor cells (Figure 1G). 
Delving deeper, we performed immunostaining for 
SOX10 in 115 human NB samples (Figure 1H). In human 
NB tissue, SOX10 expression pattern could be divided 
into neuroblasts-specific (hereinafter referred to as 
“Pattern I”) 3.5% of NB (4 patients); Schwannian stroma-
restricted (hereinafter referred to as “Pattern II”) 45.2% 
(52 patients) and SOX10-negative, 51.3% (59 patients) 
(Figure 1H and Supplementary Figure  2D). Human 
NB tissue is composed of two spatially juxtaposed cell 
types, neuroblasts and Schwann cells, both cell types 
derive from NC lineage. This tissue composition mimics 
normal embryonic development in particular resembling 
the architecture of SG including AM at the late stage of 
NC development. It is widely accepted that Schwannian 
stroma as well as intratumoral Schwann cells in NB derive 
from non-neoplastic cell rather than from a common 
neoplastic progenitor. Taking into account that SOX10 
is expressed in the glial cells in the peripheral nervous 
system during normal embryonic development, it is not 
surprising to observe its expression in NB Schwannian 
stroma. Moreover, the absence of SOX10 expression 
in tumorigenic neuroblasts in human NB tissue is in 
agreement with the lack of Sox10 expression in neurons 
of peripheral nervous system [27]. Since Schwannian 
stroma-rich NBs are defined as clinically nonaggressive, 
it explains why SOX10HIGH tumors are associated with a 
good prognosis. Taken together, our data reveal that NB 
tissue is largely devoid of the presence of cells with neural 
crest characteristics as demonstrated by the absence of 
SOX10 expression in tumorigenic compartment of NB.
Finally, we have assessed a panel of previously 
established human NB cell lines for the expression 
of SOX10 (Figure 1I). We examined the presence of 
SOX10+ cells in 15 different human NB cell lines and 
show that none of human NB cell lines revealed the 
presence of SOX10+ cells neither by Western blotting 
nor by immunostaining and RNA sequencing (Figure 1I 
and Supplementary Figure 2E, 2F). These observations 
are in agreement with the fact that NB cell lines entirely 
lack Schwannian stroma component and are primarily 
composed of neuroblasts.
The lack of SOX10 expression in tumorigenic 
compartment of NB argues against NCSC-based genetic 
program underlying NB pathogenesis. Because SOX10 
is a “master regulator” and belongs to the top of the 
regulatory transcriptional hierarchy controlling NCSC 
identity and fate, it is very unlikely that another population 
of SOX10-neagtive NCSCs is present within NB.
The SOX9-driven neural crest induction does 
not initiate NC signature in human NB cell lines
Sox9, another member of SoxE family of 
transcription factors, plays a crucial role in NC 
development [31]. It has been recently suggested by 
Kanduri and colleagues that SOX9 plays a key role 
in stem cell proliferation in human NB [33]. We have 
studied SOX9 expression in a large cohort of human NB 
samples and observed that its expression was correlated 
with unfavorable prognosis (Supplementary Figure 3A–
3E) (n = 498). While SOX9 expression did not differ 
between different stages of NB, its expression was 
increased in MYCN amplified tumors (p < 0.01), as well 
as in unfavorable samples as compared to samples with 
favorable prognosis (p < 0.05). Immunohistochemistry 
for SOX9 protein revealed that 16.5% of all samples 
(20/121) exhibited “Pattern I” (neuroblast-restricted) and 
19.8% (24/121) showed “Pattern II” (Schwannian stroma-
restricted), respectively (Figure 2A, 2B). However, the 
majority of samples (62%;75/121) were devoid of SOX9+ 
cells. Next, we investigated the expression of SOX9 in 
human NB cell lines at the RNA as well as at the protein 
level as shown in Supplementary Figure 4A, 4B. In 
striking contrast to SOX10, the expression of SOX9 
was readily detected in the majority of human NB cell 
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Figure 1: Targeting MYCN to Sox10+ NCSCs does not lead to NB formation and SOX10 is predominantly expressed 
in Schwannian stromal compartment. (A, C) Neural crest cells and their progeny at E9 (A) and E11.5 (C). (B) Immunostaining 
for Ki67 and Th in adrenal gland (AG) and suprarenal ganglia (SrG) from LSL-MYCN, and Sox10-Cre; LSL-MYCN at E18.5. Scale bars: 
50 µm. (D) Immunostaining for Th in AG from Dhh-Cre; LSL-tdTomato, and Dhh-Cre; LSL-tdTomato; LSL-MYCN mouse. Scale bars: 
50 µm. (E) Differential SOX10 expression in neuroblastoma (INSS stages (1/2, n = 199; 3/4, n = 246; 4s, n = 53), MYCN status (MNA-, 
n = 401; MNA+, n = 92) risk group (non-high, n = 322, high, n = 176) and response to treatment (favorable, n = 181; unfavorable, 
n = 91)) in cohort 1. Statistics analyzed by Kruskal-Wallis or Mann-Whitney test. (F) Kaplan-Meier curve of event-free survival (EFS) and 
overall survival (OS) of neuroblastoma patients with high and low SOX10 gene expression. (G) Sox10 staining in tumor from Th-MYCN 
and LSL-MYCN; Dbh-iCre mice. Scale bars: 25  µm. (H) Immunohistochemistry for SOX10 in human neuroblastoma tissue microarray. Pie 
chart indicates percentage and case numbers. Scale bars: 20  µm (I) Immunofluorescence for SOX10 in neuroblastoma cell lines. Positive 
control: M111031 melanoma cell line. Scale bars: 50  µm NCC: neural crest cell, NT: neural tube, NC: notochord, DA: dorsal aorta, DRG: 
dorsal root ganglia, PSG: primary sympathetic ganglia, AG: adrenal gland.
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lines (Supplementary Figure 4A) indicating that SOX9 
is present in neuroblasts. Subsequently, we investigated 
mouse NB tissue derived from TH-MYCN and LSL-
MYCN; Dbh-iCre mice. We observed Sox9+ cells and 
they morphologically resembled neoplastic neuroblasts 
(Supplementary Figure 4C, 4D, upper panels). Both 
mouse tumors appeared stroma-poor, so it might explain 
the lack of Sox9+ Schwann cells. Interestingly, no Sox9+ 
cells were present before the onset of tumor initiation as 
shown in Supplementary Figure 4C, 4D (lower panels). 
The fact that non-neoplastic tissue was devoid of Sox9-
expressing cells points towards a lack of MYCN-driven 
regulation of Sox9 expression. To test whether Sox9+ 
cells were present in the human AM, we have performed 
immunohistochemical analysis for SOX9 protein in the 
tissue at the gestational weeks 14 and 17. As shown in 
Supplementary Figure  4E, no SOX9-expressing cells were 
detected in human fetal AM. These data are in accordance 
with previously published reports demonstrating that AM 
is completely devoid of SOX9+ cells during embryonic 
development [28]. To verify our findings also in the non-
transgenic wild-type mouse tissue of AM, we took the 
advantage of Sox9 reporter mouse strain [32], a line in 
which GFP expression is driven by the endogenous Sox9 
promoter. AM did not contain any GFP+ cells, while 
they could readily be detected in the gut (Supplementary 
Figure 4F, 4G).
To validate the identity of Sox9+ cells observed in 
mouse NB tissue, we have performed the immunostaining 
for synaptophysin (SYP), a neuronal/neuroendocrine 
lineage marker, and virtually all SOX9+ cells showed 
strong SYP positivity in mouse neoplastic neuroblasts 
(100% respectively, Figure 2C). As mentioned earlier, 
both mouse tumors were stroma-poor and this observation 
could explain the lack of Sox9+ Schwann cells.
Taken together these data do not seem to support 
the stem cell identity of SOX9-expressing cells but rather 
indicate that SOX9+ cells might represent SA lineage-
restricted cell population. To test this hypothesis, we 
further investigated the molecular signature of SOX9+ 
cells. The analysis of a publicly available database of 
NB cell lines revealed that SOX9 expression was clearly 
Figure 2: SOX9 is expressed in tumorigenic neuroblasts in human and mouse neuroblastoma samples. (A) 
Immunohistochemistry for SOX9 in human neuroblastoma tissue microarray. Scale bars: 20 µm. (B) Pie chart indicates percentage and 
case numbers from the tissue microarray represented in (A). (C) Immunofluorescence for Sox9 and Syp in tumor from Th-MYCN and from 
LSL-MYCN; DBH-Cre mice. Scale bar: 50 µm.
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associated with the expression of SA lineage markers 
such as PHOX2A, PHOX2B, DBH and TH (Figure 3A). 
Moreover, no NC stem cell signature was observed in 
SOX9-expressing NB cell lines (Figure 3A).
Given its crucial role in the step of NC induction 
during development [34] and observations by Mondal 
et al., we hypothesized that SOX9 overexpression could 
suffice to induce de-novo stemness in NB cells. To test 
this hypothesis, loss- and gain-of-function studies were 
performed to manipulate the levels of SOX9 in established 
NB cell lines. Cell lines with low level of endogenous 
SOX9 expression (IMR-5, SHSY5Y, SK-N-BE (2)) were 
used to induce SOX9 overexpression and cell lines with 
high level of SOX9 expression (SK-N-AS, CHP-100) 
were used to perform SOX9 KD (schematically illustrated 
in Figure 3B). We next confirmed both overexpression and 
knock-down at the protein level as shown in Supplementary 
Figure 5A, 5B. Since both vectors (SOX9 overexpression 
and SOX9 knock-down) carried GFP sequence, we have 
decided to enrich for SOX9-altered cells and performed 
FACS sorting (Supplementary Figure 5C). Subsequently, 
we have subjected GFP-sorted cells to RNA sequencing 
(Figure 3C). We have then analyzed expression profiles 
of SOX9 activated vs SOX9 repressed genes (Figure 3D, 
3E) and observed that while the overexpression of SOX9 
altered processes such al cell migration, cell motility and 
locomotion, knock-down of SOX9 was associated with 
changes in axon guidance, nervous system development, 
synaptic transmission and regulation of exocytosis of 
neurotransmitters (Figure 3E). To functionally assess the 
relevance of the genetic changes we observed, we have 
performed several in vitro assays. To address whether 
SOX9 overexpression induced EMT-like processes, we 
have performed in vitro migration and invasion assays 
(Figure 3F, 3G). Our data demonstrated that while 
overexpression of SOX9 resulted in an enhanced migration 
and invasion in IMR-5 and SHSY5Y cells, knock-
down of SOX9 in SK-N-AS was associated with clearly 
pronounced decrease in migration and invasion (Figure 3F, 
3G and Supplementary Figure 5F). We next examined if 
SOX9 could confer oncogenic properties of NB cells and 
performed in vitro colony formation assay and in vivo 
tumor formation. As shown in Supplementary Figure 6A, 
6B, SOX9 overexpression increased number of colonies 
and knock-down of SOX9 resulted in fewer colonies and 
also significantly reduced tumor volume. To tests whether 
these oncogenic properties were associated with increased 
stemness, we have assessed sphere-forming capacities of 
SOX9-altered cells. As shown in Supplementary Figure 6C, 
overexpression of SOX9 did enhance sphere formation in 
IMR-5, SH-SY5Y and SK-N-BE (2) and reduced it in 
SK-N-AS. This result might seem counterintuitive since 
our previous data indicated that SOX9+ cells represent 
committed progenitors rather than undifferentiated stem 
cells. However, it is important to note that sphere-forming 
in vitro assay on its own is not sufficient to provide accurate 
readout of the number of stem cells. Moreover, a majority 
of our NB cultures failed to generate spheres from a single 
cell and therefore, we have decided to perform this assay in 
high-density cultures. This per se might have jeopardize the 
purity of such an assay and therefore, we cannot exclude 
that sphere fusion could influence our results.
As we have shown earlier, our RNA sequencing 
data suggested a possible role of SOX9 in neuronal 
differentiation. First, we have quantified the number 
of TH-positive cells upon SOX9 overexpression 
(Supplementary Figure 6D). In two independent 
NB cell lines, SH-SY5Y and SK-N-BE (2), SOX9-
overexpressing cells were characterized by a strong 
reduction in TH-positivity indicating significant degree of 
de-differentiation. To functionally assess whether SOX9 
plays a role in neuronal differentiation, we have performed 
retinoic acid (RA)-induced in vitro differentiation 
(Supplementary Figure 6E, 6F). As illustrated in 
Supplementary Figure 6E, cells overexpressing SOX9 
were exposed to RA for 96 hours and subjected to gene 
expression analysis for selected genes. RT-PCR revealed 
that while in control cells RA exposure induced expression 
of DBH (dopamine beta-hydroxylase), NSE (neuron-
specific enolase), SLC6A2 (norepinephrine transporter 
gene) and SYP (synaptophysin), SOX9 overexpression 
appeared to interfere with the induction of expression of 
these genes. These data indicate that an overexpression of 
SOX9 (in this particular case SOX9 overexpression level 
was nearly 100 times higher compared to control cells) can 
prevent RA-induced neuronal differentiation.
SOX neuroblastoma signature is highly 
reminiscent of sympathoadrenal progenitor 
program during embryonic development
To this end, we have identified SOX9 expression in 
neoplastic neuroblasts, characterized by the presence of 
lineage-specific markers such as synaptophysin. We also 
showed that interfering with SOX9 gene revealed its role 
in migration, invasion and differentiation. Moreover, our 
data demonstrate that SOX9 can also confer oncogenic 
properties of NB cells. However, all of these effects seem 
to be restricted to the lineage-committed SA progenitors.
To delve deeper into molecular signature of SOX9 
cells, we have dissected our RNA sequencing data 
with respect to genes specific for stem cell/progenitor/
differentiated cells stages. As shown in Figure 4A, 
several clusters were revealed including gene signature 
specific for NC stem cells, central nervous system (CNS) 
stem cells, CNS glial cells, peripheral glia, immature 
neuron/progenitor, mature neurons and SA progenitors. 
In line with our previous data, SOX10 expression was 
not changed upon SOX9 gene changes (Figure 4A). It 
is in striking contrast to early development, where Sox9 
expression is sufficient to induce NC-like phenotype and 
the expression of Sox10 [34]. On the contrary, NB cells 
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Figure 3: Oncogenic properties of SOX9 in neuroblastoma are associated with SA lineage progenitors. (A) Differential 
expression of NCSC and SA-progenitor signature genes in neuroblastoma cell lines from database 1. (B) Experimental procedure of 
harvesting pure transfected cells for RNA-sequencing. n = 3 independent samples were subjected to RNA sequencing. (C) Genes 
differentially expressed in IMR-5vetor versus IMR-5SOX9, SH-SY5Yvetor versus SH-SY5YSOX9, and SK-N-ASshns versus SK-N-ASshSOX9 cells. 
(D) Venn diagram shows overlap of SOX9 activated and repressed genes from three RNA sequencing datasets individually. For SOX9 
activated genes, only genes with significant p value and log2 fold change higher than one are selected. For SOX9 repressed genes, only 
genes with significant p value and log2 fold change less than minus one are selected. Overlapping gene numbers are indicated. (E) Gene 
ontology analysis of SOX9 activated and repressed genes commonly overlapping in either two or three datasets. Top fifteen GO results base 
on p value are shown. Bar graph shows SOX9 activated genes are involved in cell migration related categories (red), and SOX9 repressed 
genes are associated in neuron differentiation (red). (F, G) Migration (F) and invasion (G) assays of SOX9 overexpressed and knockdown 
cells. Scale bar: 50 µm. Results in (F, G) are shown as mean ± SEM and statistics are analyzed by Student’s t-test.
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seem not to follow NC scenario and fail to induce SOX10 
expression upon SOX9 overexpression.
Given the importance of this key step in NC 
formation, the lack of similar genetic program per se 
indicates that genetic resemblance between NCSCs and 
NB cells might be overstated. Among genes in CNS 
stem cell cluster, we have observed that upon SOX9 
overexpression in IMR-5 cells, expression of several key 
genes including SOX2, Nestin, NOTCH1, PAX6 and 
PDGFRA has changed. A very interesting study performed 
by Bronner and colleagues have recently demonstrated 
that ectopic expression of MYCN when targeted to NC 
in chicken embryos drives towards CNS-like identity 
concomitant with a lack of normal NC identity [47]. 
Another striking change in gene expression was associated 
with genes in SA progenitor cluster including ASCL1, 
CHGA, DBH, GATA2 and GATA3, HAND1 and HAND2, 
PHOX2a and PHOX2B as well as PNMT and TH genes 
(Figure 4A). These changes are suggestive of SOX9-
dependent SA lineage maintenance and/or differentiation 
rather than stemness-associated role.
Intriguingly, we find that the expression of several 
SOX genes has been modulated upon changes in SOX9 
gene (Figure 4B). Among all SOX genes, only two 
members, namely SOX4 and SOX11, were upregulated 
upon SOX9 overexpression and downregulated upon 
SOX9 knock-down. These results prompted us to 
investigate RNA expression of all SOX genes in a panel 
of established NB cell lines. The subsequent analysis of 
all 21 SOX genes in human NB cells demonstrated that 
three members of SOX C subgroup (SOX4, SOX11 and 
SOX12) were profoundly expressed (Figure 4C). In line 
with our previous observations, SOX10 RNA was not 
detected in any of NB cell lines analyzed (Figure 4C).
Sox4 and Sox11 are known to exert pleiotropic 
effects in the central nervous system (CNS) and peripheral 
nervous system (PNS) during embryonic development 
[35, 36]. They play a role in determining neuronal identity 
of CNS precursors, as well as driving proliferation 
and maintaining survival of SA progenitors [35]. The 
overlapping expression of Sox4 and Sox11 has been 
shown to be restricted to the immature Phox2b+/Th+ SA 
progenitors and both proteins are not expressed in NCSCs 
[35]. Loss of both proteins does not influence the number 
of Sox10+ NCSCs and glia, further demonstrating that its 
function is restricted to SA progenitors [35].
The full functional analysis of the possible role of 
SOX4, SOX11 and SOX12 is well beyond the scope of 
the current study but such experiments can provide further 
insight into our understanding of NB pathogenesis.
DISCUSSION
Despite decades of speculations, there has been no 
compelling functional evidence supporting the relevance 
of the suggested link between NCSCs and NB cells. 
Given the prominence of the CSC theory and its proven 
role in cancer initiation in a wide range of tissues, many 
researchers have assumed that NB originates from 
multipotent NCSCs. Here, we show using in vivo mouse 
models of NB, that multipotent Sox10-expressing NCSCs 
do not have the capacity to sustain oncogenic activation 
leading to NB formation. Instead, initiating oncogenic 
transformation in NCSCs results in perinatal lethality. 
Interestingly, in humans NB can occur in patients with 
Hirschsprung disease, a neurocristopathy linked to 
the impaired function of NCSCs cells [17–21]. These 
observations corroborate our findings in GEM models and 
suggest that NB can occur even in the absence of proper 
functioning of NCSCs.
On the contrary, there has also been controversy 
regarding the existence of NCSCs within NB tissue. Large 
scale sequencing data demonstrated the presence of NC-like 
transcriptional circuitry in NB cell cultures as defined by the 
expression of AP-1 [37]. NB cell lines are heterogeneous 
and include three distinct cellular phenotypes, neuroblastic 
N-type, non-neuronal substrate-adherent S-type and 
intermediate, I-type cells [38–40]. While N-type cells 
have been suggested to resemble SA progenitors, S-type 
cells have been attributed similarities to Schwann cells. 
Previously it has been proposed that NB I-type cells are 
NCSCs [41]. Our data, however, demonstrate that NB 
human cell lines lack the expression of a bona fide NCSCs 
marker, SOX10. Instead, analysis of human biopsies from 
NB patients revealed the SOX10 expression in restricted 
to the cells of NB Schwannian stroma. Based on the 
International Neuroblastoma Pathology Classification 
(INPC), four distinct diagnostic subgroups include 
ganglioneuroma, ganglioneuroblastoma (GNB) intermixed, 
GNB nodular and NB. The first three are characterized 
as Schwannian stroma-rich and are associated with good 
prognosis. NB, however, is usually SS-poor and can also 
be subdivided into undifferentiated, poorly differentiated 
and differentiated subgroups [42]. Interestingly, our data 
on the SOX10 expression in the Schwannian stroma is in 
agreement with the expression and functional role of Sox10 
in the peripheral glia during embryogenesis [26].
Given the fact that human NB cell lines were 
devoid of SOX10 expression, we attempted to initiate 
the neural crest (NC) program in NB by overexpressing 
SOX9 gene, which plays a crucial role in NC induction 
during embryonic development [34, 43, 44]. We found 
that SOX9 does not initiate stemness properties in NB 
cells, though oncogenic properties associated with EMT 
induction and impaired differentiation were acquired. 
These data suggest that oncogenic propensities of NB cells 
including its metastatic potential is mediated differently 
than in embryonic NCSCs. During embryogenesis, Sox9 
expression is not detectable in the SA lineage progenitors 
in mice [28], which in accordance with our data in mouse 
and human adrenal grand.
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Figure 4: Lack of NC induction upon SOX9 overexpression and SOX molecular signature associated with NB. (A) 
Expression fold change of NC and CNS stem cell, CNS and Peripheral Glia, Immature and Mature Neurons, and SA Progenitor genes 
in IMR-5SOX9vsVector, SH-SY5YSOX9vsVector and SK-N-ASshSOX9vsVector. (B) Expression fold change of SOX family genes in IMR-5SOX9vsVector, 
SH-SY5YSOX9vsVector and SK-N-ASshSOX9vsVector (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). (C) SOX family gene expression in 
neuroblastoma cell lines (n = 25).
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In contrast to embryogenesis, we show that a subset 
of NB cells displays SOX9-positivity both in mouse NB 
models and in human NB tissue. All SOX9-positive cells 
(100%) expressed markers of SA lineage committed 
progenitors.
Several recent publications have described the 
NB transcriptional core regulatory circuitry (CRC) [37, 
45, 46]. Our data further substantiate the role of CRC in 
NB initiation and maintenance, highlighting the origin 
of NB from SA lineage restricted progenitors. In line 
with our findings, another report suggests that ectopic 
expression of MYCN in NC domain of chicken embryos 
drives towards CNS-like identity concomitant with a 
lack of normal NC identity [47]. The notion that NB cells 
functionally resemble committed SA progenitors, while 
lacking specific stem cell program, provides a further 
understanding of NB biology and allows for better design 




Sox10-Cre (B6; CBA-Tg (Sox10-cre)1Wdr/J; 
stock number: 025807), LSL-tdTomato (B6. Cg-Gt 
(ROSA)26Sortm14(CAG-tdTomato) Hze/J; stock 
number: 007914) and Sox9-IRES-eGFP (B6;129S4-
Sox9tm1.1Tlu/J; stock number 030137) mouse strains 
were purchased from The Jackson Laboratory. Dhh-
Cre mouse strain was received from Prof. Dies Meijer, 
also available at the Jackson Laboratory (FVB (Cg)-Tg 
(Dhh-cre)1Mejr/J; stock number: 012929). Dbh-iCre 
(Tg (Dbh-icre)1Gsc) (Parlato et al., 2007) mouse line 
was donated by Prof. Hermann Rohrer. LSL-MYCN (Gt 
(ROSA)26Sortm1(CAG-MYCN,-luc) Jhsc) was received 
from the lab of Prof. Johannes H. Schulte. TH-MYCN (Tg 
(Th-MYCN)41Waw) was acquired from the NCI mouse 
repository. C57BL/6NRj mouse strain was purchased from 
Janvier Labs. Nude mice (CAnN. Cg-Foxn1<nu>/Crl 
(BALB/c-nude)) were purchased from Charles River. All 
animal experiments were performed in agreement with the 
Swiss Law and were approved by the cantonal veterinary 
office of Zurich, Switzerland.
Human tissue microarray and clinical tissue
Two neuroblastoma tissue microarrays were applied 
in this study. One slide containing 94 neuroblastoma cases 
was collected by the Children’s Hospital Zurich and the 
University Hospital of Zurich, another slide containing 
27 neuroblastoma cases was commercially available and 
acquired from US Biomax. Primary and metastatic tumor 
sections from a single neuroblastoma patient, and two 
adrenal gland sections from fetus were provided by Dr. 
Peter Bode.
Cell culture
Human neuroblastoma cell lines, CA2E, CHP-100, 
GI-ME-N, IGR-N-91, IMR-32, LAN-2, LAN-5, SH-EP, 
SK-N-DZ, and WSN were kindly provide by Dr. Annick 
Mühlethaler-Mottet. IMR-5, LAN-1, SH-SY5Y, and SK-
N-AS were obtained from University Children’s Hospital 
Zurich. SK-N-BE (2) was purchased from American type 
culture collection (ATCC). All cell lines were culture 
in DMEM/F-12 medium (Thermo Fisher Scientific) 
supplemented with 10% fetal bovine serum (Dutscher), 
1× L-glutamine (Thermo Fisher Scientific), 1× sodium 
pyruvate (Thermo Fisher Scientific), and 1× MEM non-
essential amino acids (Thermo Fisher Scientific), and 
maintained in a humidified incubator at 37° C, 5% CO
2
. 
For immunocytochemistry, cells were seeded in µ-slide 8 
well (ibidi) for culture.
Genotyping and in vivo imaging
For genotyping, mice biopsies were lysed using 
lysis buffer (5M NaCl, 2M Tris pH 8-8.5, 0.5M EDTA, 
20% SDS) and proteinase K at 55° C overnight. DNA 
was precipitated using isopropanol and centrifuged at 
14000 rpm for 30 min. A washing step was performed 
using 70% ethanol, followed by centrifugation at 14000 
rpm for 15 min. For PCR, the diluted DNA was added 
to a master mix with KAPA Taq ReadyMix (KAPA 
Biosystems), primers and performed according with 
KAPA Taq ReadyMix instructions. Primers are listed in 
supplementary information 4.
In vivo imaging system (IVIS) was used for tumor 
detection as previously described [4]. Briefly, animals 
were anesthetized and shaved using a waxing cream (Veet). 
Subsequently, animals were injected with 150 mg/kg 
of body weight with Luciferin (15 mg/ml in DPBS; 
122799, Perkin Elmer) and imaged 10 min later.
Analysis of public database of neuroblastoma 
samples and cell lines
SEQC/MAQC-III Consortium cohort (GSE49711) 
[48] contains gene expression profile from 498 
neuroblastoma samples by RNA sequencing and 
microarray. Boeva et al. cohort (GSE90683) [37] contains 
RNA sequencing profiling of 25 neuroblastoma cell 
lines and 2 neural crest cell lines. Harenza et al. cohort 
(GSE89413) [49] includes transcriptomic profiling of 39 
neuroblastoma cell lines performed by RNA sequencing. 
Kaplan-Meier curve of event free survival (EFS) and 
overall survival (OS) from SEQC/MAQC-III Consortium 
cohort were analyzed by R2: genomic analysis and 
visualization platform. Differentially gene expression 
with neuroblastoma clinical features and gene expression 
in Boeva et al. and Harenza et al cohorts were performed 
using R (version 3.5.0).
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Immunostaining
For paraffin embedded tissue, dissected mouse 
tissues were fixed in Histofix (Roth) at room temperature 
for 4 hours. Tissues were washed in PBS and dehydrated. 
Dehydrated tissues were then embedded in Paraffin 
and sections 5 µm thick were collected for histological 
analysis. Immunohistochemistry was performed 
following the instruction of VECTASTAIN ABC kit 
(Vector Laboratories). Paraffin-embedded tissue sections 
were deparaffinized and rehydrated. Antigen retrieval 
was done by incubation in citrate buffer at 110° C for 





 solution (Sigma Aldrich), washed in PBS and 
blocking buffer at room temperature was applied for 
1 hour. Incubation with PBS-diluted primary antibodies 
was performed at 4° C overnight. The slides were washed 
3 times in PBS and then incubated with HRP labeled 
polymer secondary and DAB substrate kit (Abcam) was 
used to visualize immunoreaction products. The sections 
were counterstained with hematoxylin (Biosystem) and 
mounted with EUKITT. For immunofluorescence, the 
tissue sections were blocked with 5% horse serum (Sigma 
Aldrich) and 0.1% triton X-100 (Sigma Aldrich) in PBS 
for one hour at room temperature after antigen retrieval. 
Slides were then incubated with primary antibody 
at 4° C overnight, washed in PBS and subsequently 
fluorescence conjugated secondary antibodies were 
applied for 1 hour at room temperature. At last, slides 
were mounted with fluorescence mounting medium 
(Dako) containing Hoechst (Life Technologies). For 
immunofluorescence on cryosections, slides were dried 
at room temperature and washed in PBS. Sections were 
permeabilized with 0.5% Triton X-100 for 5 minutes and 
were followed by procedure of immunofluorescence. For 
immunocytochemistry, cells were first fixed by Histofix 
for 10 minutes and then were followed by procedure of 
immunofluorescence.
Plasmids and transfection
For stable overexpression of SOX9, human SOX9 
expressing plasmid, pcDNA3-NFlag-SOX9fl (kindly 
provided by Prof. Michael Wegner), and vector control 
plasmid, pcDNA3-Flag-HA (kindly provided by Dr. Paolo 
Cinelli), were transfected into IMR-5, SH-SY5Y, SK-N-
BE (2) neuroblastoma cell lines. Transfected cells were 
selected by G418 (IMR-5: 400 µg/ml, SH-SY5Y: 600 µg/ml, 
SK-N-BE (2): 800 µg/ml) to generated stable clones. 
For transient expression of SOX9, GFP-tagged SOX9-
expressing plasmid, pCMV6-SOX9-GFP (Origene), and 
GFP-expressing plasmid, pSUPER-GFP (kindly provided 
by Prof. Michael Wegner), as control, were applied for 
transfection. Transfection was performed by JetPrime 
(Polyplus), following the producer’s instruction. For 
transient expression, cells were harvested at post-transfection 
48 hours for immunostaining, western blotting and sorting.
Gene knockdown was performed by using lentivirus 
packaged short hairpin RNA (shRNA) construct (Sigma 
Aldrich). shRNA targeting SOX9 (pLKO.1 shSOX9_
TRCN0000342824) and non-sense sequence (pLKO. 
shns), as negative control, were used for knockdown. 
To produce virus particle, HEK-293T/17 cells were co-
transfected with packaging plasmid pPAX2, envelope 
plasmid pMD2G (both kindly provided by Dr. Christian 
Britschgi), and shRNA plasmids. Removed medium 
containing transfection mixture and replaced with fresh 
medium. After 24 hours, virus-containing medium was 
harvested and filtered through 0.45  µm filter, and frozen 
at –80° C. For infection, SK-N-AS cells were seeded 
one day prior to infection. On the second day, 8 ug/ml 
of polybrene and virus-containing medium were added 
to cells and incubated overnight. Cultured medium was 
removed and replaced by fresh medium. For generation 
of stable clone, 2 µg/ml of puromycin (Santa Cruz) was 
added for selection.
Cell sorting
Cells transfected with pSUPER-GFP or pCMV6-
SOX9-GFP (Origene) were trypsinized and resuspended 
in PBS for sorting. Cells were sorted by FACSAria III 
sorter (BD). Live cells were selected by staining with 
1 µg/ml propidium iodine (PI) (Sigma) before sorting. 
Non-transfected cells, non-transfected cells with PI, 
and pSUPER-GFP transfected cell without PI served 
as control. Pre-gating for single and alive events was 
performed before setting the gate for GFP-positive events. 
Sorted cells were collected into lysis buffer from RNeasy 
Plus Micro kit (QIAGEN) for RNA isolation.
RNA sequencing and analysis
Isolated RNA from 3 independent samples (n = 3 
in each set of experiments) was submitted to Functional 
Genomic Center Zurich for sequencing. RNA sequencing 
was performed on Illumina Novaseq 6000 (Illumina). 
For following analysis, genes were selected based on p 
value lower than 0.05 and expression fold change is either 
above 2 or less than 0.5. Analysis of gene ontology was 
performed using Database for Annotation, Visualization 
and Integrated Discovery (DAVID) bioinformatics web 
tool, and gene set enrichment analysis (GSEA) was 
analyzed using GSEA software with signature gene set 
created based on published literature (Supplementary 
Information 3). The data are available under GSE133014.
Protein extraction and Western blot
Harvested cell pellet was resuspended in RIPA lysis 
buffer (Thermo Fisher Scientific) containing protease 
inhibitor (Roche) and phosphatase inhibitor (Roche). 
Supernatant was collected by centrifugation at 14000 rpm 
for 30 min in 4° C. Protein concentration was determined 
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by BCA protein assay (Thermo Fisher Scientific). Mixture 
of 30 μg protein and 4× Laemmli sample buffer (BioRad) 
was denatured at 95° C for 5 min. Protein mixture was 
loaded onto 4–20% TGX stain free precast gel (BioRad) 
for electrophoresis and transferred to PVDF membrane 
by Trans-Blot Turbo Blotting System (BioRad). The 
membrane was blocked with 5% w/v milk for 1 hour at 
room temperature and was incubated with TBS-T diluted 
primary antibodies overnight at 4° C. Membrane was 
next incubated with diluted HRP-conjugated secondary 
antibodies for 1 hour at room temperature. The blot was 
developed by adding Western Chemiluminescent HRP 
Substrate (BioRad) and the signal captured using Fusion 
FX Imaging System (Vilber).
Migration and invasion assay
Cell migration assay was performed using 8mm pore 
size transwell (Falcon). Invasion assay was performed 
using Matrigel-coated invasion chamber (Corning). 
Cells were starved in 3% FBS starving medium for 
48 hours prior to experiment. 5 × 105 starved cells in serum 
free medium were seeded in the upper chamber and the 
lower chamber was filled with 0.6 ml of culture medium, 
followed by incubation at 37° C for 24 h. Cells were fixed 
in Histofix for 10 minutes and cells that remained in the 
upper side of the membrane were removed by cotton 
swab. Migrated and invaded cells at the bottom of the 
membrane were stained with Hoechst. Ten fields (20×) of 
each transwell were imaged and number of migrated and 
invaded cells in a field was calculated.
Soft agar assay
Soft agar assay was performed by following 
instruction of CytoSelect 96-well cell transformation 
kit (Cell Biolab). Base agar matrix was prepared, 50 µl 
of agar matrix per well were loaded into a 96 well plate 
and allowed it to solidify. 5000 cells in 75 µl of cell 
suspension and agar matrix mixture were added to each 
well and allowed to solidify. 50 µl of culture medium 
was added and incubated for 7 days at 37° C, 5% CO
2
. 
After solubilizing the agar by adding solubilization 
solution, MTT solution was added and incubated 2 hours 
in dark at 37° C, 5% CO
2
. Detergent solution was added 
and incubated for 2 hours in dark at room temperature, 
followed by. Absorbance measurement at 570 nm by 
ELISA reader.
Xenograft model
For heterotopic model, 1 × 106 cells suspended in 
200 μl serum free DMEM/F12 medium were injected 
subcutaneously in the back of nude mice. Tumor growth was 
monitored and measured twice per week. Long diameter (X)
(mm) and short diameter (Y)(mm) of tumor were measured, 
and tumor volume was calculated by following equation: 
(X*Y [2])/2 (mm3) and mice were euthanized once the 
maximal tumor volume allowed was reached (X:10mm, 
Y:10mm). The experiments were performed in agreement 
with the Swiss Law and were approved by the cantonal 
veterinary office of Zurich, Switzerland.
Retinoic acid induced differentiation model
For immunocytochemistry, 10000 cells were seeded 
in µ-slide 8 well (ibidi), and 3 × 105 cells were seeded in 
6 cm dish in culture medium for qPCR. On the second day, 
medium was replaced by 1% FBS culture medium plus 
10 µM retinoic acid (RA)(Sigma Aldrich) and cultured 
for 48 hours. Medium was replaced again with RA 
contained 1% FBS medium, and cells were harvested for 
immunocytochemistry or qPCR after 48 hours of incubation.
RNA extraction, reverse transcription PCR, and 
quantitative PCR
Total RNA was extracted by RNeasy Kit (QIAGEN) 
according to instructions and 1 μg RNA was used to 
synthesize cDNA in reverse transcription PCR (RT-
PCR). RT-PCR was carried out using GoScript reverse 
transcriptase (Promega), and relative mRNA expression 
level was determined by quantitative PCR using Rotor-
Gene SYBR green PCR kit (QIAGEN). Rotor-Gene Q 
real-time PCR system was used for qPCR assay with the 
following program: initial denaturation at 95°C for 10 
minutes, 50 cycle of denaturation at 95°C for 10 seconds, 
annealing at 60°C for 10 seconds, and extension at 72° C 
for 30 seconds, final extension at 72°C for 10 minutes. 
Raw data was analyzed by ∆∆CT method and normalized 
to GAPDH.
Tumor sphere formation assay
Desired numbers of cells were suspended in 
appropriate volume of tumor sphere medium DMEM/F-12 
supplemented with 20 ng/ml epidermal growth factor 
(Peprotech), 10 ng/ml basic fibroblast growth factor 
(Peprotech), 0.4% bovine serum albumin (Roth), 
1 × Insulin-Transferrin-Selenium (Gibco), and 1× B27 
supplement (Gibco) to make cell concentration at 1 cell/µl. 
Two hundred cells were seeded in ultra-low attachment 
96-well plates (Corning), and wells at the edge of plate 
were added with PBS. Plates were sealed with Parafilm 
to prevent evaporation of medium and incubated at 37° C, 
5% CO
2
 for 10 days. Number of first passage spheres was 
counted using a phase-contrast microscope and spheres 
were then collected and trypsinized. Dissociated cells were 
used for second passage sphere formation assay.
Quantification and statistical analysis
Results were obtained from at least three 
independent experiments. Mouse numbers are indicated 
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in each figure. Data are shown as mean ± SEM, different 
group comparison test were performed as indicated in 
figures and all tests were applied unpaired and two-
tailed method. Significance of Kaplan-Meier curves 
were analyzed by log-rank test. Statistical analysis 
was performed by using GraphPad Prism 8 software, 
R (version 3.5.0), and R2: genomic analysis and 
visualization platform.
Data and code availability
RNA sequencing data have been deposited in NCBI 
Gene Expression Omnibus (GEO), accession number: 
GSE133014.
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